Columnist Jennifer Lynne assesses the effects of Pfizer's decision to halt production of its hemophilia B gene therapy, Beqvez.
Pfizer said it will discontinue gene therapy Beqvez (fidanacogene elaparvovec-dzkt), an approved hemophilia B treatment.
The companies were two years into a four-year, $400 million agreement aimed at developing and marketing gene therapies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback